EGFR-TKI不良反应管理专家共识

EGFR-TKI ADR Management Chinese Expert Consensus

表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors, EGFRTKI)如吉非替尼、厄洛替尼、埃克替尼和阿法替尼在中国已成为EGFR突变阳性的晚期非小细胞肺癌(non-small celllungcancer,NSCLC)的一线治疗药物,奥希替尼也获批用于二线治疗EGFR-T790M突变阳性的晚期NSCLC。EGFR-TKI的常见不良反应(adverse drug reaction, ADR)有皮疹、腹泻、甲沟炎、口腔粘膜炎、肝损伤、间质性肺疾病等。中国抗癌协会肺癌专业委员会根据中国国内不良反应诊疗现状,结合国际最新理论和经验,组织相关专家讨论并制定了EGFR-TKI不良反应管理中国专家共识。

ErbB receptor tyrosine kinase inhibitors(EGFR-TKI), gefitinib, erlotinib, icotinib and aftinib, which are approved as a frontline treatment for patients with non-small cell lung cancer(NSCLC) who have tumors harboring EGFR mutations in China. And osimertinib was approved in second line setting for patients with EGFRT 790 M-positive NSCLC. Rash, paronychia, diarrhea, stomatitis, liver dysfunction and(interstitial lung disease, ILD) are frequently observed in patients treated with EGFR-TKI. Chinese Society of Lung Cancer, Chinese Anti-Cancer Association, organized Chinese experts to develop the Chinese expert consensus on EGFR-TKI adverse event(AE) management based on domestic diagnosis and treatment of ADR and also incorporating international updated theory and recommendations.